Geron is a clinical-stage biopharmaceutical company focused on the development of a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Telomerase is an enzyme that enables cancer cells, including malignant progenitor cells, to maintain telomere length, which provides them with the capacity for limitless, uncontrolled proliferation. Imetelstat is designed to be an oligonucleotide that targets and binds with high affinity to the active site of telomerase, thereby directly inhibiting telomerase activity and impeding malignant cell proliferation.

Type
Public
HQ
Menlo Park, US
Founded
1990
Size (employees)
15 (est)
Website
geron.com
Geron Corporation was founded in 1990 and is headquartered in Menlo Park, US
Report incorrect company information

Key People/Management at Geron Corporation

John Scarlett

John Scarlett

President, Chief Executive Officer and Director
Olivia Bloom

Olivia Bloom

Executive Vice President, Finance, Chief Financial Officer and Treasurer
Melissa Behrs

Melissa Behrs

Executive Vice President, Business Development and Portfolio & Alliance Management
Andrew Grethlein

Andrew Grethlein

Executive Vice President, Development and Technical Operations
Stephen N. Rosenfield J.D

Stephen N. Rosenfield J.D

Executive Vice President, General Counsel and Corporate Secretary

Geron Corporation Office Locations

Geron Corporation has offices in Canton and Menlo Park
Menlo Park, US (HQ)
149 Commonwealth Dr
Canton, US
250 Royall St
Show all (2)
Report incorrect company information

Geron Corporation Financials and Metrics

Geron Corporation Financials

Geron Corporation's revenue was reported to be $1.07 m in FY, 2017
USD

Net income (Q1, 2018)

(7.2 m)

EBIT (Q1, 2018)

(7.4 m)

Market capitalization (14-Jun-2018)

675 m

Closing share price (14-Jun-2018)

3.9

Cash (31-Mar-2018)

7.9 m
Geron Corporation's current market capitalization is $675 m.
Annual
USDFY, 2016FY, 2017

Revenue

6.2 m1.1 m

General and administrative expense

18.8 m19.3 m

R&D expense

18 m11 m

Operating expense total

36.8 m30.3 m
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Revenue

35.4 m5.1 m

General and administrative expense

4 m4.3 m4.8 m4.5 m4.7 m4.7 m5.3 m

R&D expense

4.8 m4.1 m5 m4.6 m4.3 m3.4 m2.4 m

Operating expense total

8.8 m8.4 m9.8 m9.1 m9 m8 m7.8 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

13 m42.8 m21.2 m12.8 m16.3 m

Accounts Receivable

1.1 m

Inventories

Current Assets

67.1 m153.4 m115.9 m116.1 m96 m
Quarterly
USDQ1, 2018

Cash

7.9 m

Current Assets

91.1 m

PP&E

86 k

Total Assets

105.5 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(38.4 m)(35.7 m)46 k(29.5 m)(27.9 m)

Depreciation and Amortization

320 k47 k56 k81 k76 k

Inventories

Accounts Payable

(2 m)(364 k)(873 k)65 k278 k
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(9.4 m)27.2 m(8.8 m)(8.6 m)(3.6 m)(7.2 m)

Accounts Payable

1.2 m2.4 m1.2 m957 k574 k396 k235 k271 k308 k
USDY, 2018

Financial Leverage

1 x
Show all financial metrics
Report incorrect company information

Geron Corporation News and Updates

Report incorrect company information